Alumis Inc (ALMS)

Currency in USD
3.960
-0.370(-8.55%)
Closed·
4.030+0.070(+1.77%)
·
Trading near 52-week Low
ALMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.9354.365
52 wk Range
3.93531.350
Key Statistics
Prev. Close
4.33
Open
4.235
Day's Range
3.935-4.365
52 wk Range
3.935-31.35
Volume
1.79M
Average Vol. (3m)
2.84M
1-Year Change
-45.7534%
Book Value / Share
2.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALMS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.375
Upside
+540.78%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Alumis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.375
(+540.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy28.00+607.07%37.00MaintainNov 16, 2026
H.C. Wainwright
Buy9.00+127.27%15.00MaintainNov 13, 2026
Wells Fargo
Buy18.00+354.55%25.00MaintainNov 13, 2026
H.C. Wainwright
Buy15.00+278.79%-MaintainOct 05, 2026
Cantor Fitzgerald
Buy---MaintainSep 16, 2026

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.73 / --
Revenue / Forecast
1.91M / --
EPS Revisions
Last 90 days

ALMS Income Statement

Compare ALMS to Peers and Sector

Metrics to compare
ALMS
Peers
Sector
Relationship
P/E Ratio
−1.2x−43.3x−0.2x
PEG Ratio
0.44−0.040.00
Price / Book
1.4x1.9x2.6x
Price / LTM Sales
71.0x5.2x2.6x
Upside (Analyst Target)
-62.8%76.9%
Fair Value Upside
Unlock16.3%14.9%Unlock

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
28.46M21.92%112.69M
Other Institutional Investors
137.00M78.08%542.53M
Public Companies & Retail Investors
0.000.00%0.00
Total
165.46M100.00%655.22M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
AyurMaya Capital Management Fund, LP11.66%15,139,70759,953
Matrix Capital Management Company, LP11.66%15,139,70759,953

People Also Watch

82.67
CBRS
-4.93%
32.930
AAOI
-16.55%
115.25
VST
-7.17%
187.22
COHR
-12.90%
39.51
CRWV
-12.02%

FAQ

What Is the Alumis (ALMS) Stock Price Today?

The Alumis stock price today is 3.960 USD.

What Stock Exchange Does Alumis Trade On?

Alumis is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alumis?

The stock symbol for Alumis is "ALMS."

What Is the Alumis Market Cap?

As of today, Alumis market cap is 562.120M USD.

What Is Alumis's Earnings Per Share (TTM)?

The Alumis EPS (TTM) is -3.48.

From a Technical Analysis Perspective, Is ALMS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Alumis Stock Split?

Alumis has split 0 times.

How Many Employees Does Alumis Have?

Alumis has 252 employees.

What is the current trading status of Alumis (ALMS)?

As of Nov 21, 2026, Alumis (ALMS) is trading at a price of 3.960 USD, with a previous close of 4.330 USD. The stock has fluctuated within a day range of 3.935 USD to 4.365 USD, while its 52-week range spans from 3.935 USD to 31.350 USD.

What Is Alumis (ALMS) Price Target According to Analysts?

The average 12-month price target for Alumis is 25.375 USD, with a high estimate of 46 USD and a low estimate of 9 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +540.78% Upside potential.

What Is the ALMS Premarket Price?

ALMS's last pre-market stock price is 4.160 USD. The pre-market share volume is 1,810.000, and the stock has decreased by -0.170, or -3.930%.

What Is the ALMS After Hours Price?

ALMS's last after hours stock price is 4.030 USD, the stock has decreased by 0.070, or 1.770%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.